Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

Amgen had earlier begun individual negotiations with insurers, reducing the price of Repatha to the Harvard Pilgrim health plan, for example, and agreeing to refund the cost of the drug to any ...

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

The drugmaker said Repatha would start with a list price of $14,100 for a year’s worth of treatment. Developed by Amgen’s scientists, it is the second in a new class of drugs that lower ...

Repatha costs more than $14,000 a year; many of its users are likely to need it all their lives. But when it introduced its RepathaReady financial assistance program, Amgen required enrollees to ...

Amgen’s Repatha and Sanofi/Regeneron’s Praluent are competing for market share in the new class of PCSK9 inhibitors for high-risk cholesterol patients after both were approved by FDA this summer.

Commercializing Amgen's recently approved cholestserol fighter Repatha across the EU hit a road block this week when cost crunchers in the U.K. determined that the drug didn't deliver the right ...

THOUSAND OAKS, Calif., Oct. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that effective Dec. 31, 2019, Repatha® (evolocumab), an innovative treatment for patients with high ...